Bliss GVS Pharma Ltd (BLISSGVS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bliss GVS Pharma

IOL Chemicals

Guj. Themis Bio.

Morepen Labs.

Unichem Labs.

Novartis India

Gufic BioScience

Hikal

Dishman Carbogen

Panacea Biotec

Orchid Pharma

Why is Bliss GVS Pharma Ltd ?

Company has a low Debt to Equity ratio (avg) at 0 times

Poor long term growth as Net Sales has grown by an annual rate of 8.97% and Operating profit at 3.85% over the last 5 years

Flat results in Dec 25

INTEREST(9M) At Rs 10.00 cr has Grown at 51.75%
DEBTORS TURNOVER RATIO(HY) Lowest at 1.75 times
NON-OPERATING INCOME(Q) is 42.52 % of Profit Before Tax (PBT)

With ROE of 9.7, it has a Fair valuation with a 2 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 73.98%, its profits have risen by 24.6% ; the PEG ratio of the company is 0.8

Market Beating performance in long term as well as near term

Along with generating 73.98% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bliss GVS Pharma should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bliss GVS Pharma for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Bliss GVS Pharma

73.96%

1.33

55.52%

Sensex

-2.38%

-0.19

12.70%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.97%

EBIT Growth (5y)

3.85%

EBIT to Interest (avg)

13.29

Debt to EBITDA (avg)

0.78

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

0.73

Tax Ratio

31.95%

Dividend Payout Ratio

6.25%

Pledged Shares

Institutional Holding

20.33%

ROCE (avg)

12.28%

ROE (avg)

9.42%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.96

EV to EBIT

19.25

EV to EBITDA

14.76

EV to Capital Employed

2.11

EV to Sales

2.39

PEG Ratio

0.84

Dividend Yield

0.47%

ROCE (Latest)

10.53%

ROE (Latest)

9.68%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

PAT(9M)

At Rs 95.08 cr has Grown at 38.28%

ROCE(HY)

Highest at 14.76%

DEBT-EQUITY RATIO(HY)

Lowest at 0.05 times

-6What is not working for the Company

INTEREST(9M)

At Rs 10.00 cr has Grown at 51.75%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.75 times

NON-OPERATING INCOME(Q)

is 42.52 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Bliss GVS Pharma

Debt-Equity Ratio - Half Yearly

Lowest at 0.05 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Profit After Tax (PAT) - Nine Monthly

At Rs 95.08 cr has Grown at 38.28%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Nine Monthly

Higher at Rs 95.08 Cr

than preceding 12 month period ended Dec 2025 of Rs 84.30 cr

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Bliss GVS Pharma

Interest - Nine Monthly

At Rs 10.00 cr has Grown at 51.75%

over preceding nine months period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Debtors Turnover Ratio- Half Yearly

Lowest at 1.75 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Non Operating Income - Quarterly

is 42.52 % of Profit Before Tax (PBT)

MOJO Watch

The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT